BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Queensland Health
Johnson and Johnson
Deloitte
Accenture
UBS
Healthtrust
Chubb
Medtronic

Generated: January 16, 2018

DrugPatentWatch Database Preview

GALANTAMINE HYDROBROMIDE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for galantamine hydrobromide and what is the scope of galantamine hydrobromide patent protection?

Galantamine hydrobromide
is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Ltd, Barr, Impax Labs, Mylan, Sun Pharma Global, Watson Labs, Janssen Pharms, West-ward Pharms Int, Actavis Elizabeth, Apotex Inc, Dr Reddys Labs Ltd, Sandoz, Teva Pharms, Yabao Pharm, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Galantamine hydrobromide has eighty-eight patent family members in thirty-five countries and one supplementary protection certificate in one country.

There are fifteen drug master file entries for galantamine hydrobromide. Twenty-one suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for GALANTAMINE HYDROBROMIDE
Pharmacology for GALANTAMINE HYDROBROMIDE
Medical Subject Heading (MeSH) Categories for GALANTAMINE HYDROBROMIDE
Tentative approvals for GALANTAMINE HYDROBROMIDE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe4MGTABLET; ORAL
➤ Subscribe➤ Subscribe12MGTABLET; ORAL
➤ Subscribe➤ Subscribe8MGTABLET; ORAL

US Patents and Regulatory Information for GALANTAMINE HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Impax Labs GALANTAMINE HYDROBROMIDE galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 078484-001 May 27, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Watson Labs GALANTAMINE HYDROBROMIDE galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 079028-001 Dec 15, 2008 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
West-ward Pharms Int GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077608-002 Feb 11, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Impax Labs GALANTAMINE HYDROBROMIDE galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 078484-003 May 27, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077587-003 Jul 9, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077593-003 Sep 11, 2008 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Barr GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077605-001 Aug 28, 2008 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-001 Feb 28, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for GALANTAMINE HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-001 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-003 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-001 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide SOLUTION;ORAL 021224-001 Jun 22, 2001 ➤ Subscribe ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-003 Feb 28, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for GALANTAMINE HYDROBROMIDE

Supplementary Protection Certificates for GALANTAMINE HYDROBROMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00140 Netherlands ➤ Subscribe PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
Fish and Richardson
Baxter
QuintilesIMS
Covington
Healthtrust
Cantor Fitzgerald
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot